While mice harboring NRasG12D alone developed indolent myeloproliferative neoplasms (MPNs) and EZH2 deletion alone had minimal effects on hematopoiesis, combined NRasG12D and EZH2 mutations cooperatively induced MPN progression to lethal AML11. Here, EZH2 is linked to myeloproliferative disorder.